Please select the option that best describes you:
How does the CLL17 trial presented at ASH 2025 change current practice guidelines?
Should all CLL patients be candidates for fixed-duration treatments?
Answer from: Medical Oncologist at Academic Institution
The CLL17 study provides some tangential support for time limited therapy in a subset of patients that I would consider it now--those who have low risk disease with IGHV mutated (non-3-21) and absent TP53 mutation or deletion. Here we would expect patients to do quite well and long-term follow up e...
Sign In or Register to read more